Takahashi C, et al. - Utilizing the National Cancer Database, researchers attempted to explore the connection between pancreatic tumor size, neoadjuvant chemotherapy (NCT), neoadjuvant chemoradiation (NCRT), and definitive surgery (DS) on survival. Patients with pancreatic adenocarcinoma (PAC) who had neoadjuvant therapy (NT) and DS were identified. Findings revealed that the size of pancreatic cancer correlates to pathologic stage and overall survival. In all pancreatic cancer patients, NT showed a survival benefit. The most significant improvements in both tumor size >2 and <2 cm was showed by NCT. They found that in both the NCT and NCRT groups the 30- and 90-day mortality was significantly worse. The most important prognostic factor for survival specifically in patients receiving adjuvant therapy was tumor size. The use of NT in all pancreatic cancer patients was supported in this analysis.